Current Report Filing (8-k)
March 24 2017 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 23, 2017
Stemline Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-35619
(Commission File Number)
|
|
45-0522567
(IRS Employer Identification No.)
|
750 Lexington Avenue
Eleventh Floor
New York, New York 10022
(Address of Principal Executive Offices)
(646) 502-2311
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act.
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 8.01 Other Events.
On March 23, 2017, Stemline Therapeutics, Inc. announced completion of enrollment of the Stage 3 cohort of the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
A copy of such press release is being furnished as Exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by Stemline Therapeutics, Inc., dated March 23, 2017.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 24, 2017
|
Stemline Therapeutics, Inc.
|
|
(Registrant)
|
|
|
|
|
|
By
|
/s/ Kenneth Hoberman
|
|
|
Kenneth Hoberman
|
|
|
Chief Operating Officer
|
3
INDEX TO EXHIBITS
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by Stemline Therapeutics, Inc., dated March 23, 2017.
|
4
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Sep 2023 to Sep 2024